Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elimusertib + Niraparib in Advanced Solid Tumors and Ovarian Cancer
NCT04267939Phase 1Terminated
- Sponsor
- Bayer
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elimusertib in solid tumor (advanced stage) and ovarian cancer (6 arms), sponsored by Bayer. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Severity of Treatment Emergent Adverse Events and 4 more. Started Feb 2020; status: terminated.
02
Drugs
elimusertib
03
Conditions
solid tumor (advanced stage)ovarian cancer
Beyond the preview
Go deeper on NCT04267939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267939.